Significant contributions have been achieved by Iatros GmbH members in all these areas, including:

The validation of dynamic marker of viral replication in:

• Personalized anti-HCV therapy with HCV viral load as end point of combination treatment clinical trials
• The design of studies on the clinical utility of HIV DNA as a new dynamic marker and predictor of long term outcome

The design of a diagnostic/prognostic approach for congenital CMV infection

• Use a combination of informative markers and both immunological and molecular techniques to diagnose, monitor and predict the risk of disease
• The design and validation of molecular tests for the identification/selection  of patients eligible tor Herceptin treatment
• Development of PCR (HER-1 to HER-4) and ELISA tests (soluble HER-2)

The design and validation of a molecular test for monitoring CML patients under Gleevec treatment

• Development  of a specific PCR test (bcr-abl)
• The design and validation of a molecular test for monitoring follicular NON-Hodgkin patients under   anti CD19 treatment
• Development of a specific PCR test (t14;18)

The design and validation of different molecular approaches to monitor the efficacy of an in vivo activated 5-FU drug in colorectal cancer patients

• Quantitation of 3 characteristic enzymes involved in activation and catabolism